Sana Biotechnology
Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.
Top Stages
1 past transactions
Oscine Therapeutics
Acquisition in 2020
Oscine Therapeutics is a biotechnology company that originated from research at the University of Rochester Medical Center. The company focuses on developing a cell therapy platform that leverages stem cell science to transform the treatment of central nervous system (CNS) diseases. Oscine's platform generates bipotential astrocyte-oligodendrocyte glial progenitor cells, which can replace lost, damaged, or dysfunctional glial cells in patients suffering from degenerative diseases and conditions affecting white matter. By facilitating the restoration of these critical cells, Oscine Therapeutics aims to enhance research efforts and expand treatment possibilities for combating degeneration and potentially curing various CNS disorders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.